CClinicalTrials.gg
CompletedNCT03044860Updated Feb 15, 2017

Anatomical and Physiological Characterisation of the Gut Endocrine Cells in Healthy and in Patients With Type 2 Diabetes

An interventional study of Double-balloon enteroscopy (DBE) with biopsy retrieval in Type2 Diabetes, sponsored by University Hospital, Gentofte, Copenhagen. Completed. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-02-15.

Sponsored by University Hospital, Gentofte, Copenhagen · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

Investigation of the anatomical distribution of enteroendocrine cells by a systematic approach along the entire human intestinal tract in healthy individuals and patients with type 2 diabetes.

Read the detailed description

Enteroendocrine K and L cells are pivotal in regulating appetite and glucose homeostasis, but knowledge of their distribution in man is sparse and it is unknown whether alterations occur in type 2 diabetes. Twelve patients with type 2 diabetes and 12 age and BMI-matched healthy individuals underwent upper and lower double-balloon enteroscopy with mucosal biopsy retrieval from every \~30 cm of the small intestine and specific locations in the large intestine. The investigators evaluated the distribution of enteroendocrine cells (using IHC staining for their specific hormonal products) and evaluated mRNA expression of the corresponding genes along the entire intestinal tract in patients with type 2 diabetes and in healthy individuals.

02

Conditions studied

03

In context

Diabetes Mellitus

10,925 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.

This study's enrollment of 24 is below the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus.

Browse Diabetes Mellitus studies →

Lead sponsor

University Hospital, Gentofte, Copenhagen is the lead sponsor of 154 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

Type 2 diabetes patients

  • Diagnosis of type 2 diabetes (at least 3 months prior to study inclusion)
  • Treatment with diet counseling alone or combined with an glucose-lowering drugs: metformin or sulphonylurea
  • Caucasian ethnicity
  • Age >25 and \<70 years
  • Normal hemoglobin
  • Negative for autoantibodies to glutamic acid decarboxylase (GAD-65) and islet cell autoantibodies (ICA).

Healthy individuals

  • Fasting plasma glucose \<6.0 mM
  • Plasma glucose 2 hours after a 75 g-oral glucose tolerance test \<7.8 mM
  • Negative for GAD-65 antibodies and ICA
  • Caucasian ethnicity
  • Age >25 and \<70 years
  • Normal hemoglobin

Exclusion criteria

Exclusion criteria:

Type 2 diabetes patients

  • Liver disease (evaluated by alanine aminotransferase and/or aspartate aminotransferase >2 times normal value)
  • Treatment with dipeptidyl peptidase 4 inhibitors or medicine that could not be paused for 12 hours
  • Previous hysterectomy, appendectomy, cholecystectomy or caesarean
  • Sleep apnea
  • American Society of Anesthesiologists class >3
  • Allergy to soy protein or eggs
  • BMI >35 kg/m2 or any other condition that would contraindicate propofol sedation or enteroscopy.

Healthy individuals

  • Liver disease (evaluated by alanine aminotransferase and/or aspartate aminotransferase >2 times normal value)
  • Liver disease (evaluated by alanine aminotransferase and/or aspartate aminotransferase >2 times normal value)
  • Treatment with dipeptidyl peptidase 4 inhibitors or medicine that could not be paused for 12 hours
  • Previous hysterectomy, appendectomy, cholecystectomy or caesarean
  • Sleep apnea
  • American Society of Anesthesiologists class >3
  • Allergy to soy protein or eggs
  • BMI >35 kg/m2 or any other condition that would contraindicate propofol sedation or enteroscopy
  • First-degree relative(s) with type 1 or type 2 diabetes.
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Type 2 diabetes

    Adult patients with type 2 diabetes undergoing double-balloon enteroscopy (DBE) with biopsy retrieval using a DBE-device.

    Procedure: Double-balloon enteroscopy (DBE) with biopsy retrieval

  • Experimental
    Healthy

    Adult subjects without type 2 diabetes undergoing double-balloon enteroscopy (DBE) with biopsy retrieval using a DBE-device.

    Procedure: Double-balloon enteroscopy (DBE) with biopsy retrieval

Interventions

  • ProcedureDouble-balloon enteroscopy (DBE) with biopsy retrieval

    With the use of a double-balloon enteroscopy device, study participants underwent upper and lower enteroscopies with mucosal biopsy mucosal biopsy retrieval from every \~30 cm of the small intestine and specific locations in the large intestine

06

What researchers measure

Primary outcomes

  1. Evaluation of enteroendocrine cells (density and mRNA expression) in the intestinal tract.

    Using a double-balloon enteroscopy device, mucosal biopsies are obtained from the entire intestinal tract in 12 healthy individuals and 12 patients diagnosed with type 2 diabetes. The biopsies are analysed using immunohistochemistry (IHC) and mRNA expression analysis. Positively stained enteroendocrine cells (from IHC) are counted and divided by the epithelial area providing 'density' (cells/mm2). The data obtained from cell count and mRNA expression analysis present the variation in number of enteroendocrine cells (density) and the expression of hormonal products along the intestinal tract.

    Time frame: Cross-sectional study. Each participant went through two study days (upper and lower double-ballon enteroscopy, respectively)

  2. Evaluation of differences in enteroendocrine cells (density and mRNA expression) along the intestinal tract of healthy individuals compared with type 2 diabetes patients.

    Using a double-balloon enteroscopy device, mucosal biopsies are obtained from the entire intestinal tract in 12 healthy individuals and 12 patients diagnosed with type 2 diabetes. The biopsies are analysed using immunohistochemistry (IHC) and mRNA expression analysis. Positively stained enteroendocrine cells (from IHC) are counted and divided by the epithelial area providing 'density' (cells/mm2). Cell count (density) and mRNA expression data obtained from the healthy individuals and type 2 diabetes patietns are compared to evaluate potential differences between the two groups.

    Time frame: Cross-sectional study. Each participant went through two study days (upper and lower double-ballon enteroscopy, respectively)

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Gilliam-Vigh H, Jorsal T, Rehfeld JF, Pedersen J, Poulsen SS, Vilsboll T, Knop FK. Expression of Cholecystokinin and its Receptors in the Intestinal Tract of Type 2 Diabetes Patients and Healthy Controls. J Clin Endocrinol Metab. 2021 Jul 13;106(8):2164-2170. doi: 10.1210/clinem/dgab367. PubMed 34036343 ↗
  • Jorsal T, Rhee NA, Pedersen J, Wahlgren CD, Mortensen B, Jepsen SL, Jelsing J, Dalboge LS, Vilmann P, Hassan H, Hendel JW, Poulsen SS, Holst JJ, Vilsboll T, Knop FK. Enteroendocrine K and L cells in healthy and type 2 diabetic individuals. Diabetologia. 2018 Feb;61(2):284-294. doi: 10.1007/s00125-017-4450-9. Epub 2017 Sep 28. PubMed 28956082 ↗

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 15, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03044860
Lead sponsor
University Hospital, Gentofte, Copenhagen
Responsible party
Filip Krag Knop (MD, PhD, professor, University Hospital, Gentofte, Copenhagen) — Principal investigator
First posted
Feb 7, 2017
Start date
Mar 2011
Primary completion
Jun 2012
Completion
Jun 2012
Last update
Feb 15, 2017

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion